Jeune
Biotechnology company developing skin-targeted gene-delivery therapeutics for aesthetic indications. The organization uses a clinically described, skin-optimized viral gene-delivery platform to deliver genes encoding structural skin proteins (collagen and elastin) with the objective of inducing endogenous protein expression to address intrinsic and photo-induced aging. The company’s portfolio includes preclinical and early clinical programs targeting multiple collagen types and elastin.
Industries
Nr. of Employees
small (1-50)
Products
Gene-delivery candidate for Type III collagen (COL3A1)
Clinical-stage gene-delivery program designed to induce expression of type III collagen in skin to improve fine lines and wrinkles; includes first-in-human and extension cohort data.
Gene-delivery candidate for Type I collagen
Development-stage program intended to increase type I collagen expression in skin via targeted gene delivery.
Gene-delivery candidate for Elastin
Preclinical and development-stage candidate aiming to induce elastin expression in skin to improve elasticity and related aesthetic endpoints.
Combination gene-delivery candidate for Type III collagen and Elastin
Clinical candidate combining delivery of genes for type III collagen and elastin to address dynamic wrinkles; reported positive Phase 1 results for décolleté indications.
Gene-delivery candidate for Type IV collagen
Development-stage program focused on inducing type IV collagen expression in skin via targeted gene delivery.
Gene-delivery candidate for Type III collagen (COL3A1)
Clinical-stage gene-delivery program designed to induce expression of type III collagen in skin to improve fine lines and wrinkles; includes first-in-human and extension cohort data.
Gene-delivery candidate for Type I collagen
Development-stage program intended to increase type I collagen expression in skin via targeted gene delivery.
Gene-delivery candidate for Elastin
Preclinical and development-stage candidate aiming to induce elastin expression in skin to improve elasticity and related aesthetic endpoints.
Combination gene-delivery candidate for Type III collagen and Elastin
Clinical candidate combining delivery of genes for type III collagen and elastin to address dynamic wrinkles; reported positive Phase 1 results for décolleté indications.
Gene-delivery candidate for Type IV collagen
Development-stage program focused on inducing type IV collagen expression in skin via targeted gene delivery.
Expertise Areas
- Gene therapy for dermatology/aesthetics
- Preclinical pharmacology and mechanism-of-action studies
- Early-phase clinical trial conduct (Phase 1)
- In vivo dermal gene delivery
Key Technologies
- Viral vector gene delivery (HSV-1–based)
- In vivo gene therapy for dermal tissues
- Targeted dermal cell transduction
- Gene-encoded modulation of collagen and elastin
News & Updates
Report of positive results and significant aesthetic improvements from a Phase 1 study of a combination gene-delivery candidate targeting type III collagen and elastin for décolleté wrinkles.
Interim safety and efficacy results from Phase 1 cohorts evaluating a COL3A1 (type III collagen) gene-delivery candidate for lateral canthal lines and décolleté wrinkles.
Presentation reporting durability data from an extension cohort assessing a COL3A1 gene-delivery treatment for improvement of fine lines and wrinkles.
Report of Phase 1 cohort clinical safety and efficacy findings for a COL3A1 gene-delivery candidate in aesthetic indications.
Preclinical presentation describing a minimally invasive HSV-1–based therapy aimed at improving skin elasticity.
Report of positive results and significant aesthetic improvements from a Phase 1 study of a combination gene-delivery candidate targeting type III collagen and elastin for décolleté wrinkles.
Interim safety and efficacy results from Phase 1 cohorts evaluating a COL3A1 (type III collagen) gene-delivery candidate for lateral canthal lines and décolleté wrinkles.
Presentation reporting durability data from an extension cohort assessing a COL3A1 gene-delivery treatment for improvement of fine lines and wrinkles.
Report of Phase 1 cohort clinical safety and efficacy findings for a COL3A1 gene-delivery candidate in aesthetic indications.
Preclinical presentation describing a minimally invasive HSV-1–based therapy aimed at improving skin elasticity.